A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases (APPROACH)
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
2 years recurrence-free survival (2Y-RFS)
2 years
No
Korea: Food and Drug Administration
4-2012-0166
NCT01632722
June 2012
August 2016
Name | Location |
---|